Clinical Trial Update: Tongxinluo Improve High on Clopidogrel Platelet Reactivity Patients With Coronary Heart Disease [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Tongxinluo for reducing high on-clopidogrel platelet reactivity in patients with coronary artery disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Tongxinluo

Snippet

Sponsor: Han Yaling | Conditions: Coronary Artery Disease | Phase 4 | Status: COMPLETED